Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Werner Feuerer"'
Autor:
Lutz Renders, Klemens Budde, Christian Rosenberger, Rachel van Swelm, Dorine Swinkels, Frank Dellanna, Werner Feuerer, Ming Wen, Christiane Erley, Birgit Bader, Claudia Sommerer, Matthias Schaier, Karoline Meurer, Louis Matis
Publikováno v:
PLoS ONE, Vol 14, Iss 3, p e0212023 (2019)
In chronic kidney disease both renal insufficiency and chronic inflammation trigger elevated hepcidin levels, which impairs iron uptake, availability. and erythropoiesis. Here we report the two first-in-human phase 1 trials of PRS-080#22, a novel, ra
Externí odkaz:
https://doaj.org/article/936377bd297b46aa88a277ec34cc06df
Publikováno v:
The Quality Assurance Journal. 10:21-28
By 1 May 2004, all European Union (EU) member states had to implement the EU Clinical Trials Directive 2001/20/EC into national legislation to provide the basis for a common clinical trial development procedure throughout the EU. Shortly after this d
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::50238edd4c404730be501fd94182188a
https://doi.org/10.1002/qaj.358
https://doi.org/10.1002/qaj.358
Autor:
Dorine W. Swinkels, Rachel P. L. van Swelm, Werner Feuerer, Edgar Fenzl, Andreas Hohlbaum, Ulrich Moebius
Publikováno v:
Blood. 126:536-536
PRS-080#022 is a 20kD AnticalinTM protein linked to 30kD linear poly-ethylene-glycol that specifically binds to human hepcidin 25, thereby inhibiting its activity. PRS-080#022 is developed for the treatment of functional iron deficient anemia associa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::32bf4f84d75313a89fe27d0f7b8faf6b
https://doi.org/10.1182/blood.v126.23.536.536
https://doi.org/10.1182/blood.v126.23.536.536
Publikováno v:
BMC News and views. 4
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0d9b3d0b211a17d314e66974e4d5eb24
https://doi.org/10.1186/2048-4623-4-s1-p0004
https://doi.org/10.1186/2048-4623-4-s1-p0004
Autor:
Ulrich Tebbe, Albrecht Vogt, Karl-Ludwig Neuhaus, Rainer von Essen, Werner Feuerer, Walter Niederer, Karl-Friedrich Appel
Publikováno v:
The American journal of cardiology. 74(1)
Patients from 4 German multicenter studies on thrombolysis in acute myocardial infarction (AMI) were retrospectively evaluated to assess the incidence of optimal reperfusion, defined as a completely perfused infarct vessel after 90 minutes, without s
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b34647dc35b27637d0230c76653dcb1b
https://pubmed.ncbi.nlm.nih.gov/8017295
https://pubmed.ncbi.nlm.nih.gov/8017295
Publikováno v:
Clinical pharmacology and therapeutics, 2, 46, 155-162
Pharmacokinetics and systemic effects of recombinant tissue-type plasminogen activator (rt-PA) were studied in 18 healthy male volunteers after 30-minute intravenous infusions of placebo, 0.25 mg/kg rt-PA, and 0.5 mg/kg rt-PA. Highly comparable pharm
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e9a308cac7560d298a67207a0d167619
https://doi.org/10.1038/clpt.1989.120
https://doi.org/10.1038/clpt.1989.120
Autor:
Walter Niederer, Ulrich Tebbe, Karl-Ludwig Neuhaus, Susanne Jeep-Tebbe, Werner Feuerer, A. Vogt
Publikováno v:
Journal of the American College of Cardiology. 14(6):1566-1569
To improve further the patency rate of infarct-related coronary arteries, the following accelerated dosage regimen of recombinant tissue-type plasminogen activator (rt-PA) was administered to 80 patients with acute myocardial infarction of less than
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bfa1724743fa6ba7ddbfcd1c9e0902c3
Autor:
Klaus-Dieter Grosser, Karl-Ludwig Neuhaus, Werner Feuerer, Ulrich Tebbe, Berthold Schneider, Walter Niederer, Michael Weber, Abdohlhamid Sheikhzadeh, Martin Gottwik, Frank Praetorius, Guenter Alber, Hans-Wilhelm Hoepp, Winfried Haerer, Wolfgang Huhmann
Publikováno v:
Journal of the American College of Cardiology. 12:581-587
The effects of recombinant tissue plasminogen activator (rt-PA) and urokinase on patency and early reocclusion of infarct-related coronary arteries were investigated in a single blind, randomized multicenter trial in 246 patients with acute myocardia
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6a701d8db361ca24be9101a06c8a3f04
https://doi.org/10.1016/s0735-1097(88)80040-8
https://doi.org/10.1016/s0735-1097(88)80040-8
Autor:
Albrecht Vogt, Werner Feuerer, Karl Ludwig Neuhaus, Ulrich Tebbe, Karl Friedrich Appel, Rainer von Essen
Publikováno v:
Journal of the American College of Cardiology. (6):1391-1395
Objective. This study evaluated the impact of early patency of the infarct-related vessel on short-term mortality after thrombolysis for acute myocardial infarction. Background. Different thrombolytic regimens for acute myocardial infarction proved t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e63d6bdb52e78f0f254786c37303dee8
Autor:
P. Tanswell, K. H. Scholz, Werner Feuerer, Erhard Seifried, Karl-Heinz Herrmann, Ulrich Tebbe
Publikováno v:
The American journal of cardiology. 64(8)
Recombinant tissue-type plasminogen activator (rt-PA) has hitherto been administered in acute myocardial infarction as an intravenous infusion with an initial bolus of about 10% of the total dose, both due to its short half-life and to avoid possible
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f041ce87f4316e81c985f5481cfce6de
https://pubmed.ncbi.nlm.nih.gov/2505604
https://pubmed.ncbi.nlm.nih.gov/2505604